Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer [1] (multiple letters)

New England Journal of Medicine

Volumn 344, Issue 4, 2001, Pages 305-307

  Erlichman, Charles ^a   Goldberg, Richard M ^a   O'Connell, Michael J ^a   Vaiani, Monica ^b   Trippoli, Sabrina ^b   Messori, Andrea ^b   Pestalozzi, Bernhard C ^c   Pignon, Jean Pierre ^d   Ducreux, Michel ^d   Saltz, Leonard B ^e   Miller, Langdon L ^f  

^a MAYO CLINIC   (United States)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Pharmacia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; COLORECTAL TUMOR; NOTE; PATHOLOGY; COST BENEFIT ANALYSIS; ECONOMICS; SOCIOECONOMICS; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; COST-BENEFIT ANALYSIS; SURVIVAL ANALYSIS; VALUE OF LIFE;

EID: 0035945675     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101253440413     Document Type: Letter

References (0)